The Ibn Sina Pharmaceutical Industry's profit grew marginally in the second quarter of fiscal year 2024-25. 

The company's profit stood at Tk 21.08 crore in Q2.

Shares of the company went up 0.24 percent to Tk 292.30 as of mid-day trading today at the DSE.  

As a result, its consolidated earnings per share (EPS) rose slightly to Tk 6.75 in the October-December period of 2024 from Tk 6.70 in the same period the previous year, according to a disclosure on the Dhaka Stock Exchange (DSE) website. 

However, its EPS for July-December 2024 declined to Tk 9.47 from Tk 11.92 in the corresponding period of 2023.  

The company's consolidated net operating cash flow per share improved significantly to Tk 17.25 for the July-December period, compared to Tk 11.05 in the same period the previous year.

Founded in 1983, Ibn Sina is a leading player in Bangladesh's pharmaceutical sector, producing a wide range of pharmaceutical drugs, including herbal and unani medicines.